ESAB Q4 2022: diluted EPS $0.97, adj. EPS $1.05; sales +11% organic; guides 2023 EBITDA $420-440M

ESAB Corp

Q4 2022 sales $664M (+6% reported, +11% organic); net income $59M.
Diluted EPS continuing ops $0.97; core adj. diluted EPS $1.05.
Core adj. EBITDA $107M, up 10% vs $98M prior year Q4.
Completed Swift-Cut and Therapy Equipment bolt-on acquisitions.
2023 guidance: core organic growth 3-5%; core adj. EBITDA $420-440M; core adj. EPS $3.80-$4.00.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ESAB Corp reported the fourth quarter ended December 31, 2022 results: revenue $664 million, net income $59 million, EPS $0.97 diluted earnings per share from continuing operations. Guidance initiated.

Period: the fourth quarter ended December 31, 2022
Revenue: $664 million
Net income: $59 million
EPS: $0.97 diluted earnings per share from continuing operations
Guidance: initiated
Result: reported results

Exact text from the filing

ESAB Corporation reported fourth quarter sales of $664 million, an increase of 6% on a reported basis or 11% higher core organic growth before acquisitions and currency translation impacts. ESAB also reported fourth quarter GAAP net income from continuing operations attributable to ESAB of $59 million, $0.97 diluted earnings per share from continuing operations and core adjusted net income of $64 million, $1.05 diluted per share.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ESAB Corp filing history →

Source: SEC EDGAR

accession 0001877322-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.